R-CHOP in DLBCL: priming for success Comment

被引：3
|
作者：
Hertzberg, Mark [1 ]
机构：
[1] Prince Wales Hosp, Hong Kong, Peoples R China
来源：
BLOOD | 2022年 / 139卷 / 08期
关键词：
PHASE-III;
D O I：
10.1182/blood.2021013620
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In this issue of Blood, Martin et al(1) report the results of a phase 1 study evaluating a novel strategy of epigenetic priming before rituximab plus cyclo-phosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) using the hypomethylating agent CC486, an oral azacitidine, as initial treatment in patients with high-risk diffuse large B-cell lymphoma (DLBCL) or grade 3B/transformed follicular lymphoma. The authors demonstrate that the addition of CC-486 to R-CHOP shows promising clinical antitumor activity with an acceptable safety profile.
引用
收藏
页码：1121 / 1122
页数：2
相关论文
共 50 条
  • [41] Efficacy of R-COMP in comparison to R-CHOP in patients with DLBCL: A systematic review and single-arm metanalysis
    Visco, Carlo
    Pregnolato, Francesca
    Ferrarini, Isacco
    De Marco, Beatrice
    Bonuomo, Valentina
    Sbisa, Eugenio
    Fraenza, Costanza
    Bernardelli, Andrea
    Tanasi, Ilaria
    Quaglia, Francesca Maria
    Krampera, Mauro
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 163
  • [42] CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies
    Ayed O. Ayed
    Annalisa Chiappella
    Levi Pederson
    Betsy R. Laplant
    Angela Giovanna Congiu
    Gianluca Gaidano
    Michele Spina
    Alessandro Re
    Federica Cavallo
    Gerardo Musuraca
    William R. Macon
    Thomas Witzig
    Umberto Vitolo
    Grzegorz S. Nowakowski
    Blood Cancer Journal, 8
  • [43] CYCLON and NPM1 Cooperate within an Oncogenic Network Predictive of R-CHOP Response in DLBCL
    Bouroumeau, Antonin
    Bussot, Lucile
    Hamaidia, Sieme
    Garcia-Sandoval, Andrea
    Bergan-Dahl, Anna
    Betton-Fraisse, Patricia
    Duley, Samuel
    Fournier, Cyril
    Aucagne, Romain
    Adrait, Annie
    Coute, Yohann
    McLeer, Anne
    Col, Edwige
    David-Boudet, Laurence
    Raskovalova, Tatiana
    Jacob, Marie-Christine
    Vettier, Claire
    Chevalier, Simon
    Carras, Sylvain
    Lefebvre, Christine
    Algrin, Caroline
    Gressin, Remy
    Callanan, Mary B.
    Sartelet, Herve
    Bonnefoix, Thierry
    Emadali, Anouk
    CANCERS, 2021, 13 (23)
  • [44] MYC Translocations and Expression Are Clinically Important in R-CHOP Treated Patients with De Novo DLBCL.
    Johnson, Nathalie A.
    Ben-Neriah, Susanna
    Savage, Kerry J.
    Lee, Tang
    Horsman, Douglas E.
    Connors, Joseph M.
    Chan, Wing C.
    Lenz, Georg
    Wright, George
    Rimsza, Lisa M.
    Braziel, Rita M.
    Cook, James R.
    Tubbs, Raymond R.
    Weisenburger, Dennis D.
    Campo, Elias
    Rosenwald, Andreas
    Ott, German
    Delabie, Jan
    Jaffe, Elaine S.
    Staudt, Louis M.
    Gascoyne, Randy D.
    BLOOD, 2009, 114 (22) : 452 - 452
  • [45] Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP
    Bernard, Sophie
    Ghesquieres, Herve
    Casasnovas, Rene-Olivier
    Griolet, Samuel
    da Silva, Maria Gomes
    Feugier, Pierre
    Morschhauser, Franck
    Trotman, Judith
    Renaud, Loic
    Greil, Richard
    Martin Garcia-Sancho, Alejandro
    Grosicki, Sebastian
    van Eygen, Koen
    Copie-Bergman, Christiane
    Haioun, Corinne
    Thieblemont, Catherine
    BLOOD ADVANCES, 2021, 5 (15) : 2965 - 2968
  • [46] Perforation of the small intestine as an early complication of R-CHOP immunochemotherapy in patients with DLBCL - a report of two cases
    Bojo, Marcin
    Kalinka-Warzocha, Ewa
    Blasinska-Morawiec, Maria
    ONCOLOGY IN CLINICAL PRACTICE, 2013, 9 (02): : 84 - 87
  • [47] A population-based study on different regimens of R-CHOP in patients with newly diagnosed DLBCL in The Netherlands
    Issa, Djamila E.
    Dinmohamed, Avinash G.
    Wondergem, Marielle J.
    Blommestein, Hedwig M.
    Huijgens, Peter C.
    Lugtenburg, Pieternella J.
    Visser, Otto
    Zweegman, Sonja
    Chamuleau, Martine E. D.
    LEUKEMIA & LYMPHOMA, 2021, 62 (03) : 549 - 559
  • [48] Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL
    Herrmann, Ken
    Buck, Andreas K.
    Schuster, Tibor
    Abbrederis, Kathrin
    Bluemel, Christina
    Santi, Ivan
    Rudelius, Martina
    Wester, Hans-Juergen
    Peschel, Christian
    Schwaiger, Markus
    Dechow, Tobias
    Keller, Ulrich
    ONCOTARGET, 2014, 5 (12) : 4050 - 4059
  • [49] Impact of Total Dose Intensity and Relative Dose Intensity (RDI) of R-CHOP on Survival in Patients with DLBCL
    Komuro, Ayumi
    Seo, Sachiko
    Mochizuki, Nobuo
    Minami, Yosuke
    Kawasaki, Toshikatu
    BLOOD, 2018, 132
  • [50] Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup
    Jiang, Shiyu
    Qin, Yan
    Jiang, Hongxin
    Liu, Biao
    Shi, Jianming
    Meng, Fanlu
    Liu, Peng
    Yang, Jianliang
    Yang, Sheng
    He, Xiaohui
    Zhou, Shengyu
    Gui, Lin
    Liu, Hao
    Lin, Jing
    Han Han-Zhang
    Shi, Yuankai
    INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (09) : 2611 - 2620
12345